Patents by Inventor Harold Selnick

Harold Selnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220213114
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Harold SELNICK, Melissa EGBERTSON, Jan L. BRESLOW
  • Patent number: 11312723
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 26, 2022
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Manish P. Ponda, Harold Selnick, Melissa Egbertson, Jan L. Breslow
  • Publication number: 20200369677
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Harold SELNICK, Melissa EGBERTSON, Jan L. BRESLOW
  • Patent number: 10538512
    Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 21, 2020
    Assignee: The Rockefeller University
    Inventors: Manish P. Ponda, Jan L. Breslow, Harold Selnick, Melissa Egbertson
  • Publication number: 20190202811
    Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Jan L. BRESLOW, Harold SELNICK, Melissa EGBERTSON
  • Patent number: 10022461
    Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: July 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Abbas M. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
  • Publication number: 20180071412
    Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
    Type: Application
    Filed: October 4, 2017
    Publication date: March 15, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abbas M. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
  • Patent number: 9808542
    Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Abbas W. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
  • Publication number: 20170119912
    Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
    Type: Application
    Filed: June 9, 2015
    Publication date: May 4, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abbas W. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
  • Patent number: 9409924
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: August 9, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest McEachern, David Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold Selnick
  • Patent number: 8993588
    Abstract: Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: March 31, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian Bell, Harold Selnick, C. Blair Zartman
  • Publication number: 20100179166
    Abstract: Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Application
    Filed: June 2, 2008
    Publication date: July 15, 2010
    Inventors: Ian Bell, Harold Selnick, C. Blair Zartman
  • Publication number: 20080015233
    Abstract: The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: April 20, 2005
    Publication date: January 17, 2008
    Inventors: James Barrow, Georgia McGaughey, Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Shaun Stauffer, Joseph Vacca, Shawn Stachel, Craig Coburn, Matthew Stanton
  • Publication number: 20080015213
    Abstract: The present invention is directed to macrocyclic aminopyridyl compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: November 18, 2005
    Publication date: January 17, 2008
    Inventors: Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Keith Moore
  • Publication number: 20070293497
    Abstract: The present invention is directed to 2,3,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: November 18, 2005
    Publication date: December 20, 2007
    Inventors: Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, James Barrow, Shaun Stauffer, Joseph Vacca, Keith Moore, Shawn Stachel, Mattahew Stanton
  • Publication number: 20070244119
    Abstract: The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: April 15, 2005
    Publication date: October 18, 2007
    Inventors: James Barrow, Georgia McGaughey, Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Shaun Stauffer, Craig Coburn
  • Publication number: 20070197571
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: October 12, 2005
    Publication date: August 23, 2007
    Inventors: James Barrow, Craig Coburn, Melissa Egbertson, Georgia McGaughey, Melody McWherter, Lou Neilson, Kenneth Rittle, Harold Selnick, Shaun Stauffer, Zhi-Qiang Yang, Wenjin Yang, Wanli Lu, Bruce Fahr
  • Publication number: 20070142634
    Abstract: The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: December 15, 2004
    Publication date: June 21, 2007
    Inventors: James Barrow, Craig Coburn, Philippe Nantermet, Harold Selnick, Shawn Stachel, Matthew Stanton, Shaun Stauffer, Linghang Zhuang, Jennifer Davis
  • Publication number: 20070088165
    Abstract: The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: November 19, 2004
    Publication date: April 19, 2007
    Inventors: Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Shaun Stauffer, Mary Beth Young
  • Publication number: 20060293380
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: September 29, 2004
    Publication date: December 28, 2006
    Inventors: Philippe Nantermet, Hemaka Rajapakse, Harold Selnick